热门标签

新2手机管理端(www.hg108.vip):Sanofi ends cancer drug trials

时间:1个月前   阅读:2

皇冠博彩网址www.hg9988.vip)是皇冠体育官方博彩平台,开放皇冠信博彩网代理申请、博彩网会员开户的线上博彩的官方平台。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

新2手机管理端www.hg108.vip)实时更新发布最新最快的新2代理线路、新2会员线路、新2备用登录网址、新2手机管理端、新2手机版登录网址、新2皇冠登录网址。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。

上一篇:竞彩推荐:Trading ideas: Carlsberg, Pharmaniaga, Sentral REIT, AirAsia X, Inari Amertron, Hong Leong Industries, TCS, Advancecon, Tenaga, UEM Sunrise and Sapura Energy

下一篇:usdt接口(www.trc20.vip):Smaller net loss for Pos Malaysia in 2Q

网友评论